{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:51:22Z","timestamp":1782226282502,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung and Blood Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"US Office of Naval Research","doi-asserted-by":"crossref","award":["N00014-06-1-0704"],"award-info":[{"award-number":["N00014-06-1-0704"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000006","name":"US Office of Naval Research","doi-asserted-by":"crossref","award":["N00014-08-1-0058"],"award-info":[{"award-number":["N00014-08-1-0058"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Allos, Inc."},{"DOI":"10.13039\/100002429","name":"Amgen, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Angioblast"},{"DOI":"10.13039\/100006413","name":"Ariad Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001738","name":"Be the Match Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001738","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007501","name":"Blue Cross and Blue Shield Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007501","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001480","name":"The Bailey Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006432","name":"Terumo BCT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006432","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002815","name":"CellGenix","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002815","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Children's Leukemia Research Association"},{"name":"Fresenius-Biotech North America, Inc."},{"name":"Gamida Cell Teva Joint Venture Ltd."},{"DOI":"10.13039\/100004328","name":"Genentech, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Genzyme Corporation"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HistoGenetics, Inc."},{"DOI":"10.13039\/501100004072","name":"Kiadis Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004072","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical College of Wisconsin; Merck & Co, Inc."},{"DOI":"10.13039\/100011957","name":"Takeda Oncology Co.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011957","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Milliman USA, Inc."},{"name":"Miltenyi Biotec, Inc."},{"name":"National Marrow Donor Program"},{"name":"Optum Healthcare Solutions, Inc."},{"DOI":"10.13039\/100007075","name":"Osiris Therapeutics, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007075","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009155","name":"Otsuka America Pharmaceutical, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"crossref"}]},{"name":"RemedyMD"},{"name":"Sanofi; Seattle Genetics; Sigma-Tau Pharmaceuticals"},{"name":"Soligenix, Inc."},{"DOI":"10.13039\/100008761","name":"StemCyte","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008761","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008761","name":"A Global Cord Blood Therapeutics Co.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Stemsoft Software, Inc."},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007127","name":"Tarix Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007127","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Teva Neuroscience, Inc."},{"DOI":"10.13039\/100004361","name":"Texas Instruments Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004382","name":"WellPoint, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.bbmt.2014.07.009","type":"journal-article","created":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T04:02:48Z","timestamp":1405569768000},"page":"1777-1784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning"],"prefix":"10.1016","volume":"20","author":[{"given":"Olle","family":"Ringd\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Brazauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Buchbinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda J.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Halter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Jacobsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rammurti T.","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naynesh R.","family":"Kamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Kasow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasiani C.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthalagu","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry C.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Socie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed L.","family":"Sorror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Wingard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet S.","family":"Majhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.07.009_bib1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM199703273361301","article-title":"Solid cancers after bone marrow transplantation","volume":"336","author":"Curtis","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.07.009_bib2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJM199310143291603","article-title":"Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party","volume":"329","author":"Socie","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.07.009_bib3","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM198909213211203","article-title":"Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia","volume":"321","author":"Witherspoon","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.07.009_bib4","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1200\/JCO.2003.05.108","article-title":"New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors","volume":"21","author":"Baker","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.009_bib5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","article-title":"Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning","volume":"117","author":"Majhail","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.009_bib6","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","article-title":"Solid cancers after allogeneic hematopoietic cell transplantation","volume":"113","author":"Rizzo","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.009_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2141.2011.08756.x","article-title":"Secondary cancers following allogeneic haematopoietic cell transplantation in adults","volume":"154","author":"Majhail","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2014.07.009_bib8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/blood-2007-07-099283","article-title":"Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party","volume":"111","author":"Friedman","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.009_bib9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbmt.2011.12.519","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation","volume":"18","author":"Majhail","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.009_bib10","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.009_bib11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.2005.03.1765","article-title":"Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors","volume":"24","author":"Hegenbart","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.009_bib12","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.009_bib13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/bbmt.1999.v5.pm10465099","article-title":"Mixed chimerism: preclinical studies and clinical applications","volume":"5","author":"McSweeney","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.009_bib14","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2005.08.136","article-title":"Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning","volume":"23","author":"Baron","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.009_bib15","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","article-title":"Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial","volume":"13","author":"Bornhauser","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2014.07.009_bib16","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood-2003-02-0482","article-title":"HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies","volume":"102","author":"Maris","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.009_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/joim.12056","article-title":"A\u00a0prospective randomized toxicity\u00a0study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation","volume":"274","author":"Ringden","year":"2013","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.bbmt.2014.07.009_bib18","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringden","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.009_bib19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/1097-0215(20001115)88:4<672::AID-IJC24>3.0.CO;2-N","article-title":"Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries","volume":"88","author":"Garwicz","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bbmt.2014.07.009_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.07.009_bib21","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.1994.12.5.1063","article-title":"Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage","volume":"12","author":"van Leeuwen","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.009_bib22","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1200\/JCO.2003.04.100","article-title":"Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique","volume":"21","author":"Le Deley","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.009_bib23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2012.299","article-title":"Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced","volume":"27","author":"Shimoni","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.07.009_bib24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(02)08272-7","article-title":"Quantification of the completeness of follow-up","volume":"359","author":"Clark","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2014.07.009_bib25","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.009_bib26","unstructured":"Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2012. Available at: http:\/\/www.cibmtr.org"},{"key":"10.1016\/j.bbmt.2014.07.009_bib27","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","article-title":"Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival","volume":"14","author":"Weisdorf","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.07.009_bib28","unstructured":"Horner MJ, Ries LAG, Krapcho M, et\u00a0al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. Available at: http:\/\/seer.cancer.gov\/csr\/1975_2006\/"},{"key":"10.1016\/j.bbmt.2014.07.009_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J\u00a0R Stat Soc"},{"key":"10.1016\/j.bbmt.2014.07.009_bib30","unstructured":"Curado MP, Edwards B, Shin HR, et\u00a0al. Cancer incidence in five continents, Vol. IX. International Agency for Research on Cancer Scientific Publications No. 160. Lyon, France,\u00a02007."},{"key":"10.1016\/j.bbmt.2014.07.009_bib31","unstructured":"Breslow NE, Day NE. The design and analysis of cohort studies. In: Statistical methods in cancer research, Vol. II. International Agency for Research on Cancer Scientific Publications No. 82. Lyon, France,\u00a01987."},{"key":"10.1016\/j.bbmt.2014.07.009_bib32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1182\/asheducation-2008.1.142","article-title":"Old and new cancers after hematopoietic-cell transplantation","author":"Majhail","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Progr"},{"key":"10.1016\/j.bbmt.2014.07.009_bib33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/JCO.2000.18.2.348","article-title":"New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia","volume":"18","author":"Socie","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.07.009_bib34","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood.V87.9.3633.bloodjournal8793633","article-title":"Malignant neoplasms following bone marrow transplantation","volume":"87","author":"Bhatia","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.07.009_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bmt.2011.23","article-title":"Secondary solid tumors after allogeneic hematopoietic SCT in Japan","volume":"47","author":"Yokota","year":"2012","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114004352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114004352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:48:19Z","timestamp":1761058099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114004352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1083879114004352"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.07.009","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.09.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}